Article
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
The oncologist - 3 Nov 2022
Chihara Yusuke, Takeda Takayuki, Goto Yasuhiro, Nakamura Yoichi, Tsuchiya-Kawano Yuko, Nakao Akira, Onoi Keisuke, Hibino Makoto, Fukuda Minoru, Honda Ryoichi, Yamada Takahiro, Taniguchi Ryusuke, Sakamoto Sinjiro, Date Koji, Nagashima Seiji, Tanzawa Shigeru, Minato Koichi, Nakatani Koichi, Izumi Miiru, Shimose Takayuki, Kishimoto Junji, Uchino Junji, Takayama Koichi
Abstract excerpt
BACKGROUND: Osimertinib is one of the standard first-line treatments for advanced non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations, because it achieves significantly longer progression-free survival (PFS) than conventional first-line treatments (hazard ratio: 0.46). However, the efficacy and safety of osimertinib as a first-line treatment for patients aged ≥75 years...
Topics
Join the communities discussing this publication.